Wednesday, July 26, 2017
Company News: Page (1) of 1 - 03/20/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Lauren Lawrence appointed Vice President of Karmanos Cancer Network
(March 20, 2017)

DETROIT, March 20, 2017 /PRNewswire-USNewswire/ -- Lauren Lawrence, MBA, RHIA, has been promoted to vice president of Karmanos Cancer Network, effective immediately. She will report to Justin Klamerus, M.D., MMM, president of Karmanos Cancer Hospital and Karmanos Cancer Network.

Lawrence most recently served as executive director of Community-Based Programs at the Barbara Ann Karmanos Cancer Institute and assumes her new leadership role for Karmanos' network of 14 cancer centers throughout Michigan.

"I am extremely pleased to announce Lauren's promotion," said Dr. Klamerus. "She has been an outstanding leader and has demonstrated that not only does she have the administrative and leadership skills to succeed in this position, she also has the ability to bring people together within Karmanos and the entire McLaren Health Care System. She has my full confidence that she will provide the direction that we need as the state's largest cancer care and research network."

As vice president of Karmanos Cancer Network, Lawrence will provide oversight and leadership for cancer program administration, including interacting with network regional directors, radiation services leadership, site administrators and McLaren subsidiary leadership. She also will develop long-range goals, annual objectives and strategic initiatives within the network.

Other job responsibilities include developing and managing the network's fiscal operational budget; facilitating efficient network referral processes for patients to Karmanos Cancer Hospital for Phase I Clinical Trials, rare-complex surgeries, second opinions and other services; and collaborating with Karmanos and McLaren leadership to develop strategies for business development, volume growth and improved market share.

"I am excited about and energized by this new opportunity within the Karmanos Cancer Network," Lawrence said. "I share the same focus and mission that all network employees do in providing the best cancer care to all Michigan's residents. In my capacity as vice president of the network, I will work diligently to further Karmanos' cause of eliminating cancer by providing the skills that will allow the network to operate smoothly and successfully."

Prior to joining Karmanos Cancer Institute/McLaren Health Care, Lawrence was executive director of the Seidman Cancer Center at Lake Health University Hospitals in Mentor, Ohio.

She resides in Mount Pleasant.

About the Barbara Ann Karmanos Cancer Institute
Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute, a subsidiary of McLaren Health Care, is one of 47 National Cancer Institute-designated comprehensive cancer centers in the United States. Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to

To view the original version on PR Newswire, visit:

SOURCE Karmanos Cancer Institute

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:Science, Medical, Cancer, Business, Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Global Neuropsychiatric Disorders And Treatment Market Is Expected To Grow At A CAGR Of 6.2% During Forecast 2023
  • Urology Devices Global Market - Forecast to 2023
  • ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval
  • Wound Closure and Advanced Wound Care Global Market Forecast To 2023
  • Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

  • Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
  • Asia-Pacific Immunodiagnostics Analyzers and Reagents Market 2021: A 17-Country Analysis--Supplier Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review
  • Varian to Showcase Latest Radiotherapy and Radiosurgery Technologies and Software at AAPM 2017
  • American Brain Tumor Association's Annual Patient and Family Conference to Address Physical and Cognitive Symptoms and Side Effects
  • St. Jude Children's Research Hospital®, ALSAC Announce Chairs of Boards of Directors and Governors

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines